These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30418554)

  • 21. [Antibiotic resistance of some Pseudomonas aeruginosa isolates].
    Matinca D; Vancea D; Boboş C; Serban O
    Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333
    [No Abstract]   [Full Text] [Related]  

  • 22. The emergence of cefiderocol resistance in
    Teran N; Egge SL; Phe K; Baptista RP; Tam VH; Miller WR
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0100923. PubMed ID: 38063509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis.
    Letendre ED; Mantha R; Turgeon PL
    J Antimicrob Chemother; 1988 Oct; 22(4):557-62. PubMed ID: 3144526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escherichia coli aortic valve endocarditis.
    Zavascki AP; Morelle AM
    Clin Microbiol Infect; 2007 Feb; 13(2):216. PubMed ID: 17328739
    [No Abstract]   [Full Text] [Related]  

  • 25. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa.
    Reyes MP; Lerner AM
    Rev Infect Dis; 1983; 5(2):314-21. PubMed ID: 6405476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J; Fraile-Ribot P; Vázquez-Ucha JC; Cabot G; Martínez-Guitián M; Lence E; González-Bello C; Beceiro A; Rodríguez-Iglesias M; Galán-Sánchez F; Bou G; Oliver A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance profile of genetically distinct clinical Pseudomonas aeruginosa isolates from public hospitals in central Pakistan.
    Saleem S; Bokhari H
    J Infect Public Health; 2020 Apr; 13(4):598-605. PubMed ID: 31564530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis.
    Luque-Paz D; Bennis Y; Jaubert P; Dubée V; Wolff M; Mortaza S
    J Antimicrob Chemother; 2022 May; 77(6):1787-1789. PubMed ID: 35243514
    [No Abstract]   [Full Text] [Related]  

  • 30. Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'.
    Araoka H; Baba M; Takagi S; Matsuno N; Ishiwata K; Nakano N; Tsuji M; Yamamoto H; Seo S; Asano-Mori Y; Uchida N; Masuoka K; Wake A; Taniguchi S; Yoneyama A
    Scand J Infect Dis; 2010 Mar; 42(3):231-3. PubMed ID: 20001223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
    López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
    Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa.
    Sadek M; Le Guern R; Kipnis E; Gosset P; Poirel L; Dessein R; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2023 Jan; 42(1):61-66. PubMed ID: 36376766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.
    Giani T; Arena F; Pollini S; Di Pilato V; D'Andrea MM; Henrici De Angelis L; Bassetti M; Rossolini GM;
    J Antimicrob Chemother; 2018 Mar; 73(3):664-671. PubMed ID: 29216350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapsing tricuspid valve endocarditis by multidrug-resistant Pseudomonas aeruginosa in 11 years: tricuspid valve replacement with an aortic valve homograft.
    Kim MS; Chang HW; Lee SP; Kang DK; Kim EC; Kim KB
    J Cardiothorac Surg; 2015 Jun; 10():82. PubMed ID: 26051245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular characterization of Pseudomonas aeruginosa isolates resistant to all antimicrobial agents, but susceptible to colistin, in Daegu, Korea.
    Lee YC; Ahn BJ; Jin JS; Kim JU; Lee SH; Song DY; Lee WK; Lee JC
    J Microbiol; 2007 Aug; 45(4):358-63. PubMed ID: 17846591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa.
    Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A
    J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.